Cargando…
Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9
Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates cholesterol metabolism by inducing the degradation of hepatic low density lipoprotein receptors (LDLRs). Plasma PCSK9 has 2 main molecular forms: a 62 kDa mature form (PCSK9_62) and a 55 kDa, furin-cleaved form (PCSK9_55). PCSK9_55 is c...
Autores principales: | Oleaga, Carlota, Hay, Joshua, Gurcan, Emma, David, Larry L., Mueller, Paul A., Tavori, Hagai, Shapiro, Michael D., Pamir, Nathalie, Fazio, Sergio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890205/ https://www.ncbi.nlm.nih.gov/pubmed/33429337 http://dx.doi.org/10.1194/jlr.RA120000964 |
Ejemplares similares
-
Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies
por: Oleaga, Carlota, et al.
Publicado: (2021) -
Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
por: Shapiro, Michael D., et al.
Publicado: (2019) -
New developments in atherosclerosis: clinical potential of PCSK9 inhibition
por: Giunzioni, Ilaria, et al.
Publicado: (2015) -
Role of PAI-1 in hepatic steatosis and dyslipidemia
por: Levine, Joshua A., et al.
Publicado: (2021) -
Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin
por: Susan-Resiga, Delia, et al.
Publicado: (2021)